Brooke D. Rakai

713 total citations
18 papers, 549 citations indexed

About

Brooke D. Rakai is a scholar working on Molecular Biology, Hematology and Virology. According to data from OpenAlex, Brooke D. Rakai has authored 18 papers receiving a total of 549 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 6 papers in Hematology and 3 papers in Virology. Recurrent topics in Brooke D. Rakai's work include Protein Degradation and Inhibitors (11 papers), Ubiquitin and proteasome pathways (4 papers) and HIV Research and Treatment (3 papers). Brooke D. Rakai is often cited by papers focused on Protein Degradation and Inhibitors (11 papers), Ubiquitin and proteasome pathways (4 papers) and HIV Research and Treatment (3 papers). Brooke D. Rakai collaborates with scholars based in Canada, United States and Netherlands. Brooke D. Rakai's co-authors include Ewelina Kulikowski, Norman C.W. Wong, Michael C. Antle, Roger Thompson, Alexander W. Lohman, Mischa V. Bandet, Michael A. Colicos, G. Campbell Teskey, Lucas Scott and Nicholas L. Weilinger and has published in prestigious journals such as Circulation, Nature Neuroscience and Journal of the American College of Cardiology.

In The Last Decade

Brooke D. Rakai

18 papers receiving 533 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Brooke D. Rakai Canada 10 335 126 94 76 73 18 549
Gor Sarkisyan United States 10 357 1.1× 240 1.9× 18 0.2× 61 0.8× 26 0.4× 11 746
Krisztina Holló Hungary 14 135 0.4× 166 1.3× 24 0.3× 147 1.9× 12 0.2× 22 499
Filomena D’Amato Italy 14 169 0.5× 125 1.0× 74 0.8× 91 1.2× 12 0.2× 15 440
Yiqun Jiao United States 12 186 0.6× 178 1.4× 14 0.1× 36 0.5× 27 0.4× 19 485
Rebekah A. Warwick Israel 8 127 0.4× 126 1.0× 21 0.2× 145 1.9× 20 0.3× 9 337
Masahiko Nomura Japan 14 226 0.7× 78 0.6× 60 0.6× 71 0.9× 8 0.1× 34 541
Nicolás Belforte Canada 12 292 0.9× 88 0.7× 66 0.7× 82 1.1× 7 0.1× 29 575
Arianna Venturini Italy 15 371 1.1× 168 1.3× 31 0.3× 103 1.4× 6 0.1× 22 674
Johan Enquist United States 9 400 1.2× 333 2.6× 22 0.2× 55 0.7× 17 0.2× 12 576
K Saeki Japan 12 187 0.6× 105 0.8× 29 0.3× 37 0.5× 27 0.4× 30 425

Countries citing papers authored by Brooke D. Rakai

Since Specialization
Citations

This map shows the geographic impact of Brooke D. Rakai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brooke D. Rakai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brooke D. Rakai more than expected).

Fields of papers citing papers by Brooke D. Rakai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brooke D. Rakai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brooke D. Rakai. The network helps show where Brooke D. Rakai may publish in the future.

Co-authorship network of co-authors of Brooke D. Rakai

This figure shows the co-authorship network connecting the top 25 collaborators of Brooke D. Rakai. A scholar is included among the top collaborators of Brooke D. Rakai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brooke D. Rakai. Brooke D. Rakai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Gilham, Dean, Sylwia Wasiak, Brooke D. Rakai, et al.. (2023). Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal Impairment. Biomedicines. 11(6). 1663–1663. 6 indexed citations
2.
Fu, Li, Dean Gilham, Stephanie C. Stotz, et al.. (2023). Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation. International Immunopharmacology. 117. 109929–109929. 2 indexed citations
3.
Wasiak, Sylwia, Li Fu, Dean Gilham, et al.. (2023). The BET inhibitor apabetalone decreases neuroendothelial proinflammatory activationin vitroand in a mouse model of systemic inflammation. Translational Neuroscience. 14(1). 20220332–20220332. 1 indexed citations
4.
Sarsons, Christopher D., Dean Gilham, Laura Tsujikawa, et al.. (2023). Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells. Biomedicines. 11(10). 2683–2683. 1 indexed citations
5.
Wasiak, Sylwia, Laura Tsujikawa, Dean Gilham, et al.. (2022). Epigenetic BET reader inhibitor apabetalone (RVX-208) counters proinflammatory aortic gene expression in a diet induced obesity mouse model and in human endothelial cells. Atherosclerosis. 364. 10–19. 12 indexed citations
6.
Fu, Li, Sylwia Wasiak, Laura Tsujikawa, et al.. (2022). Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy. Pharmacology Research & Perspectives. 10(3). e00949–e00949. 9 indexed citations
7.
Tsujikawa, Laura, Olesya A. Kharenko, Stephanie C. Stotz, et al.. (2022). Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators. Biomedicine & Pharmacotherapy. 152. 113230–113230. 10 indexed citations
8.
Wasiak, Sylwia, Kim E. Dzobo, Brooke D. Rakai, et al.. (2020). BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes. Clinical Epigenetics. 12(1). 166–166. 31 indexed citations
9.
Kulikowski, Ewelina, Brooke D. Rakai, & Norman C.W. Wong. (2020). Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases. Medicinal Research Reviews. 41(1). 223–245. 82 indexed citations
10.
Gilham, Dean, Li Fu, Laura Tsujikawa, et al.. (2020). Abstract 14112: Apabetalone (RVX-208) Reduces ACE2 Expression in Human Cell Culture Systems, Which Could Attenuate SARS-CoV-2 Viral Entry. Circulation. 142(Suppl_3). 1 indexed citations
11.
Wasiak, Sylwia, Dean Gilham, Laura Tsujikawa, et al.. (2020). Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response In Vitro, in Mice and in Patients with Cardiovascular Disease. Cardiovascular Therapeutics. 2020. 1–12. 11 indexed citations
12.
Tsujikawa, Laura, Li Fu, Brooke D. Rakai, et al.. (2019). APABETALONE, AN EPIGENETIC BET INHIBITOR IN A PHASE 3 TRIAL, INHIBITS VASCULAR INFLAMMATION AND CELLULAR ADHESION LEADING TO BENEFICIAL OUTCOMES IN CVD PATIENTS. Journal of the American College of Cardiology. 73(9). 2063–2063. 1 indexed citations
13.
Tsujikawa, Laura, Li Fu, Christopher Halliday, et al.. (2019). Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism. Clinical Epigenetics. 11(1). 102–102. 90 indexed citations
14.
Kulikowski, Ewelina, Laura Tsujikawa, Dean Gilham, et al.. (2019). P5509Apabetalone (RVX-208) inhibits key drivers of vascular inflammation, calcification, and plaque vulnerability through a BET-dependent epigenetic mechanism. European Heart Journal. 40(Supplement_1). 1 indexed citations
15.
Weilinger, Nicholas L., Alexander W. Lohman, Brooke D. Rakai, et al.. (2016). Metabotropic NMDA receptor signaling couples Src family kinases to pannexin-1 during excitotoxicity. Nature Neuroscience. 19(3). 432–442. 201 indexed citations
16.
Rakai, Brooke D., et al.. (2014). Survival of Adult Generated Hippocampal Neurons Is Altered in Circadian Arrhythmic Mice. PLoS ONE. 9(6). e99527–e99527. 30 indexed citations
17.
Rakai, Brooke D. & Michael C. Antle. (2011). Lesion Size and Behavioral Deficits after Endothelin-1–Induced Ischemia are not Dependent on Time of Day. Journal of Stroke and Cerebrovascular Diseases. 22(4). 397–405. 13 indexed citations
18.
Antle, Michael C., Victoria M. Smith, Roxanne Sterniczuk, Glenn R. Yamakawa, & Brooke D. Rakai. (2009). Physiological responses of the circadian clock to acute light exposure at night. Reviews in Endocrine and Metabolic Disorders. 10(4). 279–291. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gor Sarkisyan Breakdown of academic impact, for papers by Krisztina Holló Breakdown of academic impact, for papers by Filomena D’Amato Breakdown of academic impact, for papers by Yiqun Jiao Breakdown of academic impact, for papers by Rebekah A. Warwick Breakdown of academic impact, for papers by Masahiko Nomura Breakdown of academic impact, for papers by Nicolás Belforte Breakdown of academic impact, for papers by Arianna Venturini Breakdown of academic impact, for papers by Johan Enquist Breakdown of academic impact, for papers by K Saeki
Rankless by CCL
2026